Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PNOC022 adaptive combination trial of ONC201 plus paxalisib for diffuse midline glioma
NL-OMON53539Phase 2Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dordaviprone and paxalisib in diffuse midline glioma (DMG), diffuse intrinsic pontine glioma (DIPG) and glioma (3 cohorts), sponsored by Princess Máxima Center for Pediatric Oncology. Primary endpoints: Progression-free survival at 6 months and Overall survival at 7 months. Started Dec 2022; status: recruiting.
02
Drugs
dordavipronepaxalisib
03
Conditions
diffuse midline glioma (DMG)diffuse intrinsic pontine glioma (DIPG)glioma
Beyond the preview
Go deeper on NL-OMON53539.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53539.